Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > COLUMN
COLUMN
-
It’s Time for Market Access to Play a Leading Role
April 22, 2016
-
Biosimilars Are the New Black
March 25, 2016
-
Technology Provides Opportunities for Medical Device Companies
February 18, 2016
-
Don’t Accept the Offer
January 22, 2016
-
It’s Your Choice
December 18, 2015
-
Ask a Question and Shut Up
November 27, 2015
-
Recruiternomics
October 30, 2015
-
Pharma Companies in JPAC Are Searching for the Goldilocks Candidate
September 25, 2015
-
No… Your Company Is Not like a Family!
August 28, 2015
-
What’s Your Pharma Company’s Brand in Japan?
July 24, 2015
-
Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
-
Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
-
The Mastery of Recruitment
June 26, 2015
-
“Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
-
The Truth about Recruiters
April 21, 2015
-
When Interviewing, Share the Love
March 27, 2015
-
Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
-
Eliminating Bias from the Interview Process
January 23, 2015
-
Loss Aversion: Why Candidates Reject Offers
December 26, 2014
-
What You Don’t Know About Communication Can Hurt You
November 28, 2014
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…